Trump administration pushing new drug spending cap
Axios– November 24, 2019
The Trump administration is pushing for a monthly cap on what seniors pay out-of-pocket for drugs through Medicare’s pharmacy benefit to be added to a bipartisan drug pricing bill in the Senate, a senior administration official told Axios’ Caitlin Owens and me.
The big picture: The cost of prescription drugs is still a top priority of the administration, even amidst all of the impeachment furor — and the president could very much use a big win on the subject heading into the 2020 election.
- Most of the administration’s major drug pricing policies have been tabled, are tied up in the courts or have yet to be implemented.
Between the lines: One unexpected side effect of impeachment is that it has dragged drug prices to the front of Trump’s mind again, the official said.
- Trump has been talking and meeting frequently with Republican lawmakers as part of his impeachment defense strategy.
- But, the official said, after the members discuss impeachment for a brief while with the president they usually pivot quickly and use their time with Trump to push their priorities.
- For many of these members of Congress, lowering drug prices is one of the most urgent demands they hear from their constituents. They want to be able to run on this issue in 2020 and they’re urging Trump to lean on Senate Republicans to pass a bill.
- Trump would not support Nancy Pelosi’s bill, so the only chance is the bill sponsored by Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.), the official said.
Details: The Grassley-Wyden bill currently caps enrollee cost-sharing in Part D at $3,100 a year beginning in 2022. The official said the administration is working with members to spread that cap out on a monthly basis.
- “Some seniors may max out in January, and that’s a big hit. And rather than have them spend that [on a] credit card and be in debt for 12 months or even longer … they could stagger that, and it would be a great benefit for them,” the official said.
- Grassley hinted at these changes last week, saying that the updated version of the bill “will improve the out-of-pocket cap by giving seniors and Americans with disabilities more flexibility when it comes to upfront costs.”
Recent Posts
-
SCPC Releases Third Installment of Video Series on the Unique Role of Long-Term Care Pharmacies
Long‑term care pharmacies play a specialized and indispensable role in supporting seniors and medically complex patients across the country. Unlike traditional retail pharmacies, LTC pharmacies provide coordinated, around‑the‑clock clinical support, enhanced medication management, and seamless collaboration with caregivers and providers to ensure continuity of care for those who need it most. This week’s featured video […]
-
SCPC Urges CMS Not to Apply Retail Drug Pricing Benchmarks to Long-Term Care Pharmacies
On November 2, 2026, the Senior Care Pharmacy Coalition (SCPC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the agency’s proposed extension of the information collection associated with the National Average Drug Acquisition Cost (NADAC) survey. While supporting efforts to improve transparency in prescription drug pricing, SCPC emphasized that […]
-
SCPC Releases New Video on the Next Chapter for Long-Term Care Pharmacy
SCPC’s new video, ‘LTC Pharmacy is Rising’, explores how we’re turning our sector’s growing momentum into a strong voice in Washington. Behind every LTC pharmacy are people committed to caring for our country’s most vulnerable patients. Hear from SCPC’s President & CEO, Esmé Grewal, and VP of Government Relations, Shara Selonick, about what drives their […]
Stay Connected
Get the latest news and updates on issues impacting the long-term care pharmacy community.